Skip Navigation



Annals of Oncology Advance Access published online on February 25, 2005
Annals of Oncology, doi:10.1093/annonc/mdi122
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/4/579    most recent
mdi122v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Weinfurt, K. P.
Right arrow Articles by Schulman, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinfurt, K. P.
Right arrow Articles by Schulman, K. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received September 9, 2004
Accepted November 23, 2004

Original article

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

K. P. Weinfurt 1*, Y. Li 1, L. D. Castel 1, F. Saad 2, J. W. Timbie 1, G. A. Glendenning 3, and K. A. Schulman 1

1 Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
2 Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Québec, Canada
3 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

* To whom correspondence should be addressed.
K. P. Weinfurt, E-mail: kevin.weinfurt{at}duke.edu


  Abstract

Background: We examined the clinical relevance of skeletal-related events (SREs) for health state preferences, pain and health-related quality of life in patients with advanced prostate cancer and a history of bone metastases.

Patients and methods: Data were from a clinical trial of zoledronic acid versus placebo in the treatment of SREs associated with advanced prostate cancer metastatic to bone. Patients (n=248) were included if they experienced an SRE during the study. Outcome measures were assessed at fixed intervals. We used mixed-effects models to estimate changes in outcomes after each patient's first SRE.

Results: There were clinically meaningful and statistically significant declines in physical well-being after: radiation and pathologic fractures; functional well-being after radiation; and emotional well-being after radiation and pathologic fractures. There also were meaningful and significant declines in preference and utility scores after radiation and fracture. Pain intensity declined after radiation, but not after other SREs; no other pain measure changed substantively.

Conclusions: SREs have important and significant effects on measures of health-related quality of life in men with prostate cancer. Treatments that prevent SREs may not demonstrate corresponding effects on outcomes if the effects of SREs occur between scheduled outcome assessments. Implications for trial design are discussed.

Keywords: antineoplastic agents; bone neoplasms; diphosphonates; prostatic neoplasms; quality of life; research design.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Ann. Onc., March 1, 2008; 19(3): 420 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. P. Weinfurt, K. J. Anstrom, L. D. Castel, K. A. Schulman, and F. Saad
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer
Ann. Onc., June 1, 2006; 17(6): 986 - 989.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Tanvetyanon
Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K. P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584)
Ann. Onc., October 1, 2005; 16(10): 1712 - 1713.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bernhard
Timing of quality of life assessment in cancer clinical trials: fine tuning remains a challenge
Ann. Onc., April 1, 2005; 16(4): 523 - 524.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.